Arshad M. Khanani, MD, MA
Show Description +
Arshad M. Khanani, MD, MA, discusses 2-year data from the GATHER2 trial, with patients re-randomized in the second year to monthly or every-other-month treatment with avacincaptad pegol (Izervay, Iveric Bio/Astellas) or sham.
Posted: 11/08/2023
Arshad M. Khanani, MD, MA
Arshad M. Khanani, MD, MA, discusses 2-year data from the GATHER2 trial, with patients re-randomized in the second year to monthly or every-other-month treatment with avacincaptad pegol (Izervay, Iveric Bio/Astellas) or sham.
Posted: 11/08/2023
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2023.
Please log in to leave a comment.